Dishman Carbogen Amcis Limited (DCAL), a prominent player in the pharmaceutical industry, has successfully increased its authorized share capital, as approved by shareholders through a special resolution passed via postal ballot on September 19, 2025.

Key Highlights of the Capital Increase

• Increase Amount: The company has raised its authorized share capital by Rs. 3.95 crores.
• New Shares Created: An additional 1,97,50,000 equity shares of Rs. 2 each were created.
• Total Authorized Capital: The move has elevated the total authorized share capital from Rs. 34.05 crores to Rs. 38.00 crores.
• Total Equity Shares: The number of equity shares has increased from 17,02,50,000 to 19,00,00,000.

Shareholder Approval Process

The special resolution for altering the Capital Clause of the Memorandum of Association (MoA) was passed through a postal ballot. The e-voting period commenced on August 21, 2025, at 9:00 AM (IST) and concluded on September 19, 2025, at 5:00 PM (IST). The results were confirmed through a scrutinizer's report dated September 19, 2025.

Additional Resolutions Passed

Along with the capital increase, shareholders also approved several other significant resolutions:

1. Raising funds through the issue of equity shares or other eligible securities.
2. Re-appointment of Mrs. Deohooti J. Vyas as a Whole-time Director.
3. Confirmation of Mr. Dhaval Rameshchandra Shah's appointment as a Non-Executive and Non-Independent Director.

Implications for Dishman Carbogen Amcis

This increase in authorized share capital provides Dishman Carbogen Amcis with enhanced financial flexibility. It potentially allows the company to issue new shares for various corporate purposes, which may include raising additional capital, funding expansion plans, or other strategic initiatives.

The company's move to increase its authorized capital, coupled with the approval for raising funds through various methods, suggests that Dishman Carbogen Amcis might be preparing for future growth or investment opportunities.

Dishman Carbogen Amcis Limited, a global Contract Development and Manufacturing Organization (CDMO), has reported robust financial performance for the Last Twelve Months (LTM) ending Q1 FY26, showcasing significant growth and improved financial metrics.

Revenue and Profitability

The company reported revenue of INR 28,958.00 million for LTM Q1 FY26, representing a 9.10% Compound Annual Growth Rate (CAGR) from FY21 to FY25. This growth demonstrates the company's strong market position and increasing demand for its services.

Dishman Carbogen Amcis has maintained a healthy profitability profile, with an EBITDA margin of 20.10% for LTM Q1 FY26. The company's contribution margin stood at an impressive 81.60%, indicating efficient cost management and value addition in its operations.

Order Book and Client Base

The company's future outlook appears promising, with a robust order book of INR 23,094.00 million for FY26. This strong pipeline reflects the confidence of its clients in Dishman Carbogen Amcis's capabilities and services.

Serving over 200 customers globally, the company has established long-standing relationships with an average tenure of more than 16 years for its top clients. This client loyalty underscores the company's reputation for quality and reliability in the pharmaceutical industry.

Operational Highlights

Dishman Carbogen Amcis operates across 10 manufacturing sites globally, with capabilities spanning drug substance, drug product, and specialty chemicals. The company's expertise in high-value areas, including high potency APIs and antibody-drug conjugates (ADCs), positions it well in the competitive CDMO market.

The company's pipeline includes 28 late-stage molecules and 19 commercial projects, indicating a strong potential for future revenue growth. Additionally, Dishman Carbogen Amcis has entered into co-investment agreements with a large Japanese innovator, further solidifying its market position.

Financial Position

The company has significantly improved its financial position, with the Net Debt to EBITDA ratio decreasing from 5.30x in FY23 to 2.80x in LTM Q1 FY26. This improvement reflects better cash flow management and a stronger balance sheet.

Strategic Initiatives

Dishman Carbogen Amcis is focusing on several strategic initiatives to drive future growth:

1. Expanding into niche high-growth areas such as ADCs
2. Implementing operational and cost efficiency measures
3. Pursuing green chemistry and sustainability initiatives
4. Enhancing IT transformation and AI for faster development
5. Closer integration between Dishman and CARBOGEN AMCIS operations

Investor Presentation

In a recent investor presentation filed with the stock exchanges, Dishman Carbogen Amcis highlighted its strong market position and growth strategies. The presentation, dated September 4, 2025, provides insights into the company's financial performance, operational capabilities, and future outlook.

Harshil Dalal, Global Chief Financial Officer of Dishman Carbogen Amcis, stated, "Our robust financial performance and improved metrics demonstrate the success of our strategic initiatives and the growing demand for our services in the global pharmaceutical market."

As Dishman Carbogen Amcis continues to leverage its expertise in complex, high-value molecules and expand its global presence, the company appears well-positioned for sustained growth in the competitive CDMO industry.